About Us

Archives






Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

Posted: October 5, 2021 at 6:08 pm


LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

Visit link:
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.